Ikena Oncology Q3 EPS $(0.40) Beats $(0.43) Estimate, Sales $1.19M Miss $2.55M Estimate
Portfolio Pulse from Benzinga Newsdesk
Ikena Oncology reported Q3 losses of $(0.40) per share, beating the analyst consensus estimate of $(0.43) by 6.98%. However, the company's quarterly sales of $1.19 million missed the analyst consensus estimate of $2.55 million by 53.53%. This represents a 16.67% increase in losses and a 81.49% decrease in sales compared to the same period last year.
November 09, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Ikena Oncology's Q3 earnings beat estimates but sales significantly missed expectations. This mixed result could lead to uncertainty in the market.
Ikena Oncology's Q3 earnings beat analyst estimates, which could be seen as a positive signal. However, the significant miss on sales could be a cause for concern, potentially leading to uncertainty about the company's performance and impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100